Human LILRB5/CD85c/LIR-8 Antibody Summary
Arg18-His456
Accession # O75023
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
LILRB5/CD85c/LIR-8 in Transfected & Wild Type HEK293 Human Embryonic Kidney Cell Line. LILRB5/CD85c/LIR-8 was detected in immersion fixed Transfected & Wild Type HEK293 Human Embryonic Kidney Cell Line using Mouse Anti-Human LILRB5/CD85c/LIR-8 Monoclonal Antibody (Catalog # MAB30651) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to Cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: LILRB5/CD85c/LIR-8
LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1, 2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4) It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5). Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiopoietin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).
- Brown, D. et al. (2004) Tissue antigens. 64:215.
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
- Hogan, H. E. et al. (2016) Sci Rep. 6:21780.
- Zheng, J. et al. (2012) Nature 485:656.
- Siddigui, M. et al. (2017) Eur. Heart J. 38:3569.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human LILRB5/CD85c/LIR-8 Antibody
There are currently no reviews for this product. Be the first to review Human LILRB5/CD85c/LIR-8 Antibody and earn rewards!
Have you used Human LILRB5/CD85c/LIR-8 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image